Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors

被引:26
|
作者
Lu, Yipin [1 ]
Knapp, Mark [1 ]
Crawford, Kenneth [2 ]
Warne, Robert [2 ]
Elling, Robert [1 ]
Yan, Kelly [2 ]
Doyle, Michael [2 ]
Pardee, Gwynn [2 ]
Zhang, Li [2 ]
Ma, Sylvia [2 ]
Mamo, Mulugeta [1 ]
Ornelas, Elizabeth [1 ]
Pan, Yue [1 ]
Bussiere, Dirksen [1 ]
Jansen, Johanna [1 ]
Zaror, Isabel [2 ]
Lai, Albert [2 ]
Barsanti, Paul [1 ]
Sim, Janet [2 ]
机构
[1] Novartis Inst Biomed Res, Global Discovery Chem, Emeryville, CA 94608 USA
[2] Novartis Inst Biomed Res, Oncol, Emeryville, CA 94608 USA
关键词
ATR; PI3K alpha; mutant; crystal structure; ATR inhibitor; PROTEIN-KINASE-A; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DISCOVERY; POTENT; THERAPY; IDENTIFICATION; DETERMINANTS;
D O I
10.1016/j.jmb.2017.04.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATR, a protein kinase in the PIKK family, plays a critical role in the cell DNA-damage response and is an attractive anticancer drug target. Several potent and selective inhibitors of ATR have been reported showing significant antitumor efficacy, with most advanced ones entering clinical trials. However, due to the absence of an experimental ATR structure, the determinants contributing to ATR inhibitors' potency and specificity are not well understood. Here we present the mutations in the ATP-binding site of PI3K alpha to progressively transform the pocket to mimic that of ATR. The generated PI3K alpha mutants exhibit significantly improved affinity for selective ATR inhibitors in multiple chemical classes. Furthermore, we obtained the X-ray structures of the PI3K alpha mutants in complex with the ATR inhibitors. The crystal structures together with the analysis on the inhibitor affinity profile elucidate the roles of individual amino acid residues in the binding of ATR inhibitors, offering key insights for the binding mechanism and revealing the structure features important for the specificity of ATR inhibitors. The ability to obtain structural and binding data for these PI3K alpha mutants, together with their ATR-like inhibitor binding profiles, makes these chimeric PI3K alpha proteins valuable model systems for structure-based inhibitor design. (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecomnnons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1684 / 1704
页数:21
相关论文
共 43 条
  • [41] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Engelman, Jeffrey A.
    Chen, Liang
    Tan, Xiaohong
    Crosby, Katherine
    Guimaraes, Alexander R.
    Upadhyay, Rabi
    Maira, Michel
    McNamara, Kate
    Perera, Samanthi A.
    Song, Youngchul
    Chirieac, Lucian R.
    Kaur, Ramneet
    Lightbown, Angela
    Simendinger, Jessica
    Li, Timothy
    Padera, Robert F.
    Garcia-Echeverria, Carlos
    Weissleder, Ralph
    Mahmood, Umar
    Cantley, Lewis C.
    Wong, Kwok-Kin
    NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
  • [42] Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
    Morales, Guillermo A.
    Garlich, Joseph R.
    Su, Jingdong
    Peng, Xiaodong
    Newblom, Jessica
    Weber, Kevin
    Durden, Donald L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (05) : 1922 - 1939
  • [43] A Group of Novel HIF-1α Inhibitors, Glyceollins, Blocks HIF-1α Synthesis and Decreases Its Stability via Inhibition of the PI3K/AKT/mTOR Pathway and Hsp90 Binding
    Lee, Sun-Hee
    Jee, Jun-Goo
    Bae, Jong-Sup
    Liu, Kwang-Hyoen
    Lee, You Mie
    JOURNAL OF CELLULAR PHYSIOLOGY, 2015, 230 (04) : 853 - 862